Domestic pharmaceutical companies have difficult on expanding prescription amount of domestic anticancer treatments
It was identified that domestic pharmaceutical companies have difficult on expanding prescription amount of domestic anticancer treatments due to high entry barrier compared to that of hypertensive treatment or diabetes treatment. In the case of chronic leukemia treatment 'Gleevec', after patent ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
